Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Xvivo Perfusion

BATS-CHIXE:XVIVOS
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XVIVOS
BATS-CHIXE
SEK3B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Xvivo Perfusion AB (publ), a medical technology company, develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Xvivo Perfusion has significant price volatility in the past 3 months.
XVIVOS Share Price and Events
7 Day Returns
10.5%
BATS-CHIXE:XVIVOS
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-
BATS-CHIXE:XVIVOS
-0.3%
GB Medical Equipment
-23.6%
GB Market
XVIVOS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Xvivo Perfusion (XVIVOS) 10.5% -17% -37.9% - - -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • No trading data on XVIVOS.
  • No trading data on XVIVOS.
Price Volatility
XVIVOS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Xvivo Perfusion undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Xvivo Perfusion to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Xvivo Perfusion.

BATS-CHIXE:XVIVOS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:XVIVOS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 22%) (0.19%))
0.872
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.87
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.872 * 5.44%)
5.27%

Discounted Cash Flow Calculation for BATS-CHIXE:XVIVOS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Xvivo Perfusion is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:XVIVOS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 5.27%)
2020 -33.50 Analyst x1 -31.82
2021 8.35 Analyst x2 7.53
2022 47.00 Analyst x1 40.28
2023 77.94 Est @ 65.84% 63.46
2024 113.99 Est @ 46.24% 88.16
2025 151.07 Est @ 32.53% 110.98
2026 185.71 Est @ 22.93% 129.60
2027 215.81 Est @ 16.21% 143.06
2028 240.64 Est @ 11.51% 151.53
2029 260.40 Est @ 8.21% 155.76
Present value of next 10 years cash flows SEK858.00
BATS-CHIXE:XVIVOS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK260.40 × (1 + 0.53%) ÷ (5.27% – 0.53%)
SEK5,518.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK5,518.83 ÷ (1 + 5.27%)10
SEK3,301.09
BATS-CHIXE:XVIVOS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK858.00 + SEK3,301.09
SEK4,159.09
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK4,159.09 / 26.60
SEK156.35
BATS-CHIXE:XVIVOS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:XVIVOS represents 0.9982x of OM:XVIVO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.9982x
Value per Share
(Listing Adjusted, SEK)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 156.35 x 0.9982
SEK156.07
Value per share (SEK) From above. SEK156.07
Current discount Discount to share price of SEK111.40
= -1 x (SEK111.40 - SEK156.07) / SEK156.07
28.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Xvivo Perfusion is available for.
Intrinsic value
29%
Share price is SEK111.4 vs Future cash flow value of SEK156.07
Current Discount Checks
For Xvivo Perfusion to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Xvivo Perfusion's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Xvivo Perfusion's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Xvivo Perfusion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Xvivo Perfusion's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:XVIVOS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK0.19
OM:XVIVO Share Price ** OM (2020-04-07) in SEK SEK111.6
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Xvivo Perfusion.

BATS-CHIXE:XVIVOS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:XVIVO Share Price ÷ EPS (both in SEK)

= 111.6 ÷ 0.19

599.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xvivo Perfusion is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Xvivo Perfusion is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Xvivo Perfusion's expected growth come at a high price?
Raw Data
BATS-CHIXE:XVIVOS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 599.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
72.2%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:XVIVOS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 599.2x ÷ 72.2%

8.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xvivo Perfusion is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Xvivo Perfusion's assets?
Raw Data
BATS-CHIXE:XVIVOS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK21.71
OM:XVIVO Share Price * OM (2020-04-07) in SEK SEK111.6
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:XVIVOS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:XVIVO Share Price ÷ Book Value per Share (both in SEK)

= 111.6 ÷ 21.71

5.14x

* Primary Listing of Xvivo Perfusion.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xvivo Perfusion is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Xvivo Perfusion's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Xvivo Perfusion has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Xvivo Perfusion expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
72.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Xvivo Perfusion expected to grow at an attractive rate?
  • Xvivo Perfusion's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Xvivo Perfusion's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Xvivo Perfusion's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:XVIVOS Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:XVIVOS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 72.2%
BATS-CHIXE:XVIVOS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 28.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:XVIVOS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:XVIVOS Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 483 71 82 3
2021-12-31 350 34 46 3
2020-12-31 221 32 9 2
2020-04-07
BATS-CHIXE:XVIVOS Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 221 30 5
2019-09-30 217 34 12
2019-06-30 203 23 7
2019-03-31 193 15 9
2018-12-31 188 24 13
2018-09-30 171 34 13
2018-06-30 162 38 13
2018-03-31 153 33 10
2017-12-31 148 22 6
2017-09-30 145 8 0
2017-06-30 145 6 0
2017-03-31 142 5 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Xvivo Perfusion's earnings are expected to grow significantly at over 20% yearly.
  • Xvivo Perfusion's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:XVIVOS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Xvivo Perfusion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:XVIVOS Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.06 3.75 2.37 2.00
2021-12-31 1.72 2.57 0.69 3.00
2020-12-31 0.33 0.48 0.18 2.00
2020-04-07
BATS-CHIXE:XVIVOS Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 0.19
2019-09-30 0.44
2019-06-30 0.26
2019-03-31 0.32
2018-12-31 0.48
2018-09-30 0.51
2018-06-30 0.49
2018-03-31 0.39
2017-12-31 0.25
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Xvivo Perfusion is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Xvivo Perfusion's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Xvivo Perfusion has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Xvivo Perfusion performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Xvivo Perfusion's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Xvivo Perfusion has delivered over 20% year on year earnings growth in the past 5 years.
  • Xvivo Perfusion's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Xvivo Perfusion's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.
Earnings and Revenue History
Xvivo Perfusion's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Xvivo Perfusion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:XVIVOS Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 220.84 4.94 92.57 62.65
2019-09-30 216.81 11.73 85.65 57.25
2019-06-30 203.39 6.90 85.67 52.15
2019-03-31 193.04 8.56 78.59 51.36
2018-12-31 187.87 12.69 70.47 47.93
2018-09-30 171.05 13.37 68.32 45.49
2018-06-30 162.40 12.92 67.11 42.64
2018-03-31 153.34 10.11 62.22 41.08
2017-12-31 148.34 6.26 63.75 39.47
2017-09-30 145.19 0.10 60.10 40.38
2017-06-30 144.66 -0.09 62.93 40.53
2017-03-31 142.12 0.34 60.57 38.64
2016-12-31 138.18 1.50 55.70 36.67
2016-09-30 132.44 4.90 55.61 33.52
2016-06-30 127.33 6.77 45.74 32.00
2016-03-31 121.96 6.29 46.15 32.48
2015-12-31 120.25 5.13 45.21 31.09
2015-09-30 113.11 3.50 41.56 33.08
2015-06-30 108.92 3.64 39.72 31.23
2015-03-31 98.26 3.35 36.86 26.11
2014-12-31 84.70 5.22 33.77 23.12
2014-09-30 79.19 6.41 32.74 18.24
2014-06-30 73.55 6.51 31.65 17.10
2014-03-31 70.85 7.48 29.98 15.97
2013-12-31 68.92 8.05 29.07 15.19
2013-09-30 63.61 4.92 30.18 12.51
2013-06-30 62.49 1.73 29.79 10.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Xvivo Perfusion has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Xvivo Perfusion used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Xvivo Perfusion's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Xvivo Perfusion's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Xvivo Perfusion has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Xvivo Perfusion's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Xvivo Perfusion's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Xvivo Perfusion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Xvivo Perfusion's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Xvivo Perfusion's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Xvivo Perfusion has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Xvivo Perfusion Company Filings, last reported 3 months ago.

BATS-CHIXE:XVIVOS Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 577.52 0.00 159.95
2019-09-30 582.62 6.41 197.64
2019-06-30 573.54 7.26 198.22
2019-03-31 542.59 7.91 176.48
2018-12-31 540.48 0.00 187.06
2018-09-30 534.63 0.00 201.25
2018-06-30 535.33 0.00 209.04
2018-03-31 508.21 0.00 193.51
2017-12-31 504.33 0.00 195.32
2017-09-30 498.19 0.00 200.82
2017-06-30 501.15 0.00 203.04
2017-03-31 315.67 0.00 16.52
2016-12-31 316.48 0.00 24.87
2016-09-30 316.21 0.00 40.05
2016-06-30 316.96 0.00 41.78
2016-03-31 185.00 0.00 42.72
2015-12-31 184.87 0.00 41.23
2015-09-30 179.16 0.00 42.60
2015-06-30 177.56 0.00 41.64
2015-03-31 179.77 0.00 39.66
2014-12-31 178.42 0.00 48.20
2014-09-30 173.18 0.00 55.06
2014-06-30 169.72 15.90 2.52
2014-03-31 98.33 11.81 2.13
2013-12-31 96.64 6.66 4.13
2013-09-30 94.40 5.97 2.96
2013-06-30 93.47 0.08 1.16
  • Xvivo Perfusion has no debt.
  • Xvivo Perfusion currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • Xvivo Perfusion has no debt, it does not need to be covered by operating cash flow.
  • Xvivo Perfusion has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Xvivo Perfusion's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Xvivo Perfusion has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Xvivo Perfusion's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Xvivo Perfusion dividends. Estimated to be 0% next year.
If you bought SEK2,000 of Xvivo Perfusion shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Xvivo Perfusion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Xvivo Perfusion's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:XVIVOS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:XVIVOS Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Xvivo Perfusion has not reported any payouts.
  • Unable to verify if Xvivo Perfusion's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Xvivo Perfusion's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Xvivo Perfusion has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Xvivo Perfusion's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Xvivo Perfusion's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Xvivo Perfusion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Xvivo Perfusion has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Xvivo Perfusion's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Magnus Nilsson
COMPENSATION SEK9,173,000
AGE 63
TENURE AS CEO 9.3 years
CEO Bio

Dr. Magnus Nilsson, Ph.D., has been the Chief Executive Officer of Xvivo Perfusion AB since 2011. Dr. Nilsson served as the Chief Executive Officer and President of Vitrolife AB (publ) from January 2003 to October 31, 2011. He served as Project Manager of pharmaceutical development at Pharmacia & Upjohn AB from April 1993 to March 1998. He also served as Project Manager for pre-clinical and clinical pharmaceutical development projects at KaroBio AB from December 1987 to March 1993. He had been a Director of Immunicum AB (publ) since 2014 until 2019. He serves a Director at Dignitana AB. He served as a Director of Vitrolife from 1999 to 2000. He served as Director of Xvivo Perfusion AB (publ) until May 13, 2016. He was a Board member of CMA Microdialysis AB from 2004 to March 2011. Dr. Nilsson received the Doctor of Medical Science from the University of Uppsala in 1987.

CEO Compensation
  • Magnus's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Magnus's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Xvivo Perfusion management team in years:

6.3
Average Tenure
50
Average Age
  • The average tenure for the Xvivo Perfusion management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Magnus Nilsson

TITLE
MD & CEO
COMPENSATION
SEK9M
AGE
63
TENURE
9.3 yrs

Christoffer Rosenblad

TITLE
CFO, Deputy CEO
AGE
44
TENURE
8.3 yrs

Henrik Isaksson

TITLE
Operations Director
AGE
48
TENURE
1.5 yrs

Christer de Flon

TITLE
AGE
70

Pär-Ola Larsson

TITLE
Marketing and Sales Director of EMEA & Pacific
AGE
50
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the Xvivo Perfusion board of directors in years:

2
Average Tenure
59.5
Average Age
  • The average tenure for the Xvivo Perfusion board of directors is less than 3 years, this suggests a new board.
Board of Directors

Gösta Johannesson

TITLE
Chairman of the Board
COMPENSATION
SEK205K
AGE
60
TENURE
2 yrs

Camilla Öberg

TITLE
Director
COMPENSATION
SEK130K
AGE
55
TENURE
3.9 yrs

Folke Nilsson

TITLE
Director
COMPENSATION
SEK130K
AGE
69
TENURE
7.3 yrs

Yvonne Mårtensson

TITLE
Director
COMPENSATION
SEK130K
AGE
66
TENURE
2 yrs

Alan Raffensperger

TITLE
Director
COMPENSATION
SEK130K
AGE
59
TENURE
2 yrs

Dag Andersson

TITLE
Director
AGE
58
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
X
Management checks
We assess Xvivo Perfusion's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Xvivo Perfusion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Xvivo Perfusion AB (publ), a medical technology company, develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.

Details
Name: Xvivo Perfusion AB (publ)
XVIVOS
Exchange: BATS-CHIXE
Founded: 1998
SEK2,862,213,369
26,600,496
Website: http://www.xvivoperfusion.com
Address: Xvivo Perfusion AB (publ)
Box 53015,
Gothenburg,
Västra Götaland County, 400 14,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM XVIVO Share Capital OMX Nordic Exchange Stockholm SE SEK 08. Oct 2012
OTCPK XVIP.F Share Capital Pink Sheets LLC US USD 08. Oct 2012
LSE 0RKL Share Capital London Stock Exchange GB SEK 08. Oct 2012
BATS-CHIXE XVIVOS Share Capital BATS 'Chi-X Europe' GB SEK 08. Oct 2012
Number of employees
Current staff
Staff numbers
51
Xvivo Perfusion employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 20:44
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/09
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.